OBJECTIVES: To estimate the resource utilization and related costs for Polish acromegalic patients treated with lanreotide AUTOGEL 120 mg (ATG120)  in routine  clinical practice METHODS: Medical care resource (dosage regimens, diagnostic procedures, hospitalizations, out-patient visits, any treatment changes) were collected during 1-year retrospective phase of non-intreventional, observational study (Lanro-Study). The study population consisted of  acromegalic patients treated for at least three injections with ATG120.  The endpoints were: proportion of patients treated for acromegaly with a given pharmaceutical in a given dosing interval, resource utilization, costs per patient/month or year. Costs were calculated in PLN  from the public health-care payer perspective for the year 2013 (1 EURO = 4.2 PLN).   RESULTS: 143 patients were included in the analysis (72% women, 80% macroadenoma, 72% previous pituitary surgery). Changes in the treatment scheme were reported in 54 patients. The mean cost of treatment in patients who switched from octreotide LAR (LAR) to ATG120 (n=26) was 6060.01 PLN/patient/month with LAR and 4047.96/patient/month PLN when switched to ATG120. At the time all patients entered the prospective phase, and were receiving ATG120, the mean cost of treatment with ATG120 was estimated at 3941.84 PLN/patient/month. Most patients  (n=100; 70%) received ATG120 at dosing intervals less frequent than every 4 weeks. Patients were predominantly treated in out-patient setting with 4.77 physician visits/patient/year, most common control examinations were magnetic resonance imaging of brain and brain stem (0.57/patient/year), ultrasound of neck (0.55/patient/year), and IGF-1 (1.96/patient/year), GH (1.49/patient/year), glycemia (0.91/patient/year), pituitary-thyroid axis hormones (TSH- 0.45/patient/year, T4-0.49/patient/year). Only 7.7% patients were hospitalized. The mean medical cost, excluding pharmacotherapy, was 1002 PLN/patient/year.  CONCLUSIONS: These results represent the current use of ATG120 in the population of Polish acromegalic patients in a realistic clinical settings and indicate that this therapy may provide cost saving in comparison to octreotide LAR.